Stavudine dosage and administration: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Stavudine}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (...")
 
No edit summary
 
Line 3: Line 3:
{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{AZ}}


==Dosage and Administration==


The interval between doses of ZERIT (stavudine) should be 12 hours. ZERIT may be taken with or without food.


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) POWDER, FOR SOLUTION [E.R. SQUIBB & SONS, L.L.C.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7745cad8-720d-4755-87c7-9147c0915b0f | publisher =  | date =  | accessdate =  }}</ref>
'''Recommended Adult Dosage'''
 
The recommended adult dosage is based on body weight as follows:
 
For patients weighing less than 60 kg: 30 mg every 12 hours.
For patients weighing at least 60 kg: 40 mg every 12 hours.
 
'''Recommended Pediatric Dosage'''
 
For newborns from birth to 13 days old: 0.5 mg/kg given every 12 hours.
For pediatric patients at least 14 days old and weighing less than 30 kg: 1 mg/kg given every 12 hours.
For pediatric patients weighing at least 30 kg: use the recommended adult dosage.
 
===Dosage Adjustment===
 
===Renal Impairment===
 
'''Adult Patients''': ZERIT may be administered to adult patients with impaired renal function with an adjustment in dosage as shown in Table 1.
 
{|
|[[File:Doseadjust.JPG|600px|thumb]]
|}
 
'''Pediatric Patients''': Since urinary excretion is also a major route of elimination of stavudine in pediatric patients, the clearance of stavudine may be altered in children with renal impairment. There are insufficient data to recommend a specific dose adjustment of ZERIT in this patient population.
 
===Method of Preparation for Oral Solution===
 
Prior to dispensing, the pharmacist must constitute the dry powder with purified water to a concentration of 1 mg stavudine per mL of solution, as follows:
 
Add 202 mL of purified water to the container.
Shake container vigorously until the powder dissolves completely. Constitution in this way produces 200 mL (deliverable volume) of 1 mg/mL stavudine solution. The solution may appear slightly hazy.
Dispense solution in original container with measuring cup provided. Instruct patient to shake the container vigorously prior to measuring each dose and to store the tightly closed container in a refrigerator, 2°C to 8°C (36°F to 46°F). Discard any unused portion after 30 days.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) POWDER, FOR SOLUTION [E.R. SQUIBB & SONS, L.L.C.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7745cad8-720d-4755-87c7-9147c0915b0f | publisher =  | date =  | accessdate =  }}</ref>


==References==
==References==

Latest revision as of 07:29, 3 January 2014

Stavudine
Zerit® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Dosage and Administration

The interval between doses of ZERIT (stavudine) should be 12 hours. ZERIT may be taken with or without food.

Recommended Adult Dosage

The recommended adult dosage is based on body weight as follows:

For patients weighing less than 60 kg: 30 mg every 12 hours. For patients weighing at least 60 kg: 40 mg every 12 hours.

Recommended Pediatric Dosage

For newborns from birth to 13 days old: 0.5 mg/kg given every 12 hours. For pediatric patients at least 14 days old and weighing less than 30 kg: 1 mg/kg given every 12 hours. For pediatric patients weighing at least 30 kg: use the recommended adult dosage.

Dosage Adjustment

Renal Impairment

Adult Patients: ZERIT may be administered to adult patients with impaired renal function with an adjustment in dosage as shown in Table 1.

Pediatric Patients: Since urinary excretion is also a major route of elimination of stavudine in pediatric patients, the clearance of stavudine may be altered in children with renal impairment. There are insufficient data to recommend a specific dose adjustment of ZERIT in this patient population.

Method of Preparation for Oral Solution

Prior to dispensing, the pharmacist must constitute the dry powder with purified water to a concentration of 1 mg stavudine per mL of solution, as follows:

Add 202 mL of purified water to the container. Shake container vigorously until the powder dissolves completely. Constitution in this way produces 200 mL (deliverable volume) of 1 mg/mL stavudine solution. The solution may appear slightly hazy. Dispense solution in original container with measuring cup provided. Instruct patient to shake the container vigorously prior to measuring each dose and to store the tightly closed container in a refrigerator, 2°C to 8°C (36°F to 46°F). Discard any unused portion after 30 days.[1]

References

  1. "ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) CAPSULE, GELATIN COATED ZERIT (STAVUDINE) POWDER, FOR SOLUTION [E.R. SQUIBB & SONS, L.L.C.]".

Adapted from the FDA Package Insert.